• Gefitinib, via EGFR inhibition, prevented lipid peroxidation, antioxidant enzymes damage, myocardial hypertrophy, myocardial damage and improved Ca2+ homeostasis in STZ-induced cardiomyopathy. Here, EGFR is linked to cardiomyopathy.